lundi 30 mars 2020


Cambridge Epigenetix and NuGEN Technologies Sign Partnership Agreement to Combine Leading Technologies in Epigenetics Research

Par Rédaction , dans Communiqués , le 21 août 2017

Tuesday, August 15th 2017 at 2:52pm UTC

Co-exclusive global licence covers manufacture and integration of
CEGX TrueMethyl
® technology for oxidative
bisulfite sequencing (oxBS-Seq) with Targeted Methylation and NuGEN
Ovation Methyl-Seq systems

CAMBRIDGE, England–(BUSINESS WIRE)– Cambridge
Epigenetix
(CEGX) and NuGEN
Technologies
, leaders in innovative epigenetic technologies, today
announced that they have entered into a partnership agreement to
integrate the CEGX TrueMethyl
technology for oxidative bisulfite sequencing (oxBS-Seq) with NuGEN’s
innovative NGS library preparation kits. The signing of the agreement
will enable CEGX to focus on its epigenetic biomarker discovery
programmes, both in-house and in partnership with leading biopharma
companies, and will further strengthen NuGEN’s epigenetics portfolio of
whole genome Methyl-Seq,
Reduced
Representation Bisulfite Sequencing (RRBS)
, and patented SPET target
enrichment systems.

This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20170815005705/en/

The epigenetic DNA modifications 5-hydroxymethylcytosine (5hmC) and
5-methylcytosine (5mC) play very different roles in gene regulation.
Cambridge Epigenetix enhanced the appreciation of 5hmC through the
introduction of its TrueMethyl oxBS-Seq system. Their developments have
enabled researchers to further elucidate the role of DNA methylation in
disease occurrence and progression, highlighting the potential for such
epigenetic marks in the development of improved diagnostic and
prognostic assays. The integration of TrueMethyl
oxBS
and NuGEN’s patented library preparation technologies will
broaden the scope of accessible samples for the detection of these
emerging markers.

Jason Mellad, CEO at Cambridge Epigenetix, commented: “This
partnership will enable both CEGX and NuGEN to leverage our strengths to
facilitate advances in the epigenetics field. CEGX is committed to
realising the promise of epigenetics through the development of
improved, minimally invasive diagnostic and prognostic tests for
accurate and early detection of a range of diseases, including cancer.
We are working with leading biopharma companies as well as progressing
our own high-value internal programmes, applying our expertise and
advanced proprietary technology for robust biomarker identification,
particularly from liquid biopsy samples. NuGEN’s reach and reputation
for delivering high-quality genomics solutions to the market makes them
the ideal partner to further develop TrueMethyl technology to deliver a
range of new products to enhance epigenetics research.”

Nitin Sood, CEO at NuGEN Technologies, said: “We are delighted to
be working with CEGX to provide the tools to improve the understanding
and appreciation of epigenetics in cellular function. The goal of all of
our products has always been to maximize the information that our
customers obtain from their nucleic acid samples. By combining the
TrueMethyl oxBS technology with our NGS library preparation kits, we
will provide our customers with whole genome and targeted methylation
products to unlock the tremendous potential of epigenetics. The
combination provides access to more detailed, higher resolution
epigenetic information in an integrated, cost-effective solution. The
technology complements our Methyl-Seq
and Single
Primer Enrichment Technology
product lines, and we are delighted to
provide researchers with the most comprehensive solution for epigenetics
research.”

New products resulting from this partnership are anticipated by the end
of the year and will be available directly from NuGEN. TrueMethyl
products should still be ordered through CEGX until further notice. For
more information about TrueMethyl, including how to order, please visit https://www.cambridge-epigenetix.com/products.

Notes to Editors

About Cambridge Epigenetix

Cambridge Epigenetix’s mission is to improve health through the routine
measurement of the epigenome. Cambridge Epigenetix utilizes innovative
technologies, often based on fundamental chemistry, to detect the
epigenetic biomarkers that will be most useful in clinical settings.
Spun-out of the University of Cambridge in 2012, the Company was founded
by Professor Sir Shankar Balasubramanian (co-inventor of Solexa
sequencing) and Dr Bobby Yerramilli-Rao to commercialise its founding
technology, oxidative bisulfite sequencing (oxBS-Seq), which enables
users to quantify, and discriminate between, functionally-distinct DNA
modifications – impossible with traditional bisulfite methods. Cambridge
Epigenetix is a privately held company headquartered in Cambridge, UK,
supported by several high-profile investors: GV (Google Ventures),
Sequoia, Syncona, New Science Ventures and the University of Cambridge.
The Company is seeking partnerships across a broad range of applications
in life sciences, as well as developing its own pipeline. For more
information, visit www.cambridge-epigenetix.com.

About NuGEN

Based in San Carlos, California, NuGEN Technologies, Inc. provides
innovative NGS and genomic sample prep products for a broad range of
sample types including RNA and DNA from whole tissues, FFPE samples,
single cells and liquid biopsies. NuGEN’s products offer rapid and
simple workflows designed to reduce time and cost per sample. NuGEN
products are used by 1000s of customers in basic research, applied
markets and molecular diagnostics. NuGEN products are manufactured under
stringent quality controls (ISO 13485). NuGEN provides sales and
technical support staff in North America, Europe, and Asia. To learn
more about NuGEN, visit www.nugen.com.

Contacts

Media enquiries:
Zyme Communications
Lorna Cuddon, +44
(0)7811 996 942
lorna.cuddon@zymecommunications.com

Source: NuGEN Technologies, Inc.

Étiquettes : , , , , , , , , , , , ,